If Neuren were to become a fully fledged Pharma and develop...

If Neuren were to become a fully fledged Pharma and develop NNZ-2591 for many indications themselves I believe $1000 a share (in perhaps 5-8 years) is not unreasonable when you look at the market potential the drug appears to have.

However, considering the capital and global manpower that would be needed to develop and market for Autism, Alzheimer’s, Parkinson’s, Multiple Sclerosis, etc this scenario does seem an unlikely route for Neuren to take.

But this potential value is still worth thinking about because this is the value opportunity any aquirer will be getting. As I've already mentioned (to much laughter) I think the longer term capital value NNZ-2591 may generate is at least equal to the GLP-1 anti obesity drugs ie $500b. This is the market value of Noro Novodisk.

You could make the argument that NNZ-2591's importance may be far greater than GLP-1. Obesity is a common health issue, but CNS disorders are arguably a more serious and debilitating health issue - particularly with an ageing population worldwide.